Disease

Insulin Resistance

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · INTERVENTIONAL STUDY

Dietary Macronutrients and Metabolic Markers

ClinicalTrials.gov

This is a completed interventional study with 120 participants and defined metabolic endpoints, but the registry record contains no results, only study design and planned outcomes.

PreliminaryThe Jerzy Kukuczka Academy of Physical Education in Katowice Ketogenic Diet Thyroid Function

Reported

Planned enrollment120

Intervention duration12 weeks

Primary outcome: TSHChange from baseline to 12 weeks

AUG 19, 2026 · OBSERVATIONAL STUDY

FABP4 Response After Roux-en-Y Gastric Bypass

ClinicalTrials.gov

Retrospective observational cohort study with small sample size (n=28) and no published results reported in this registry record; recruitment completed but outcomes not yet disclosed.

PreliminaryObesity (BMI>30)Insulin Resistance Istanbul University

Reported

Sample size28

Primary outcome measureChange in serum FABP4 level from baseline t…

Assessment time pointsBaseline, 3 months, 6 months

AUG 7, 2026 · PHASE 2 TRIAL

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

ClinicalTrials.gov

This is a registry record for a planned Phase 2 interventional trial that has not yet begun recruitment; no results are reported and the study design alone cannot establish efficacy or safety.

PreliminaryObesity Mirabegron Insulin Resistance

Reported

Planned enrollment60

Study phasePHASE2

Primary outcome measureChanges in Insulin sensitivity index (SI) o…